The Denmark-based pharmaceutical company Novo Nordisk has opened a hemostasis research facility within the New Jersey Economic Development Authority’s Technology Center in North Brunswick. Novo Nordisk Research U.S. will create opportunities for scientists to collaborate with the area’s leading academic institutions and industries in developing new therapies for the treatment of life-threatening bleeding. “There are a number of research organizations in the United States that are recognized for their excellence. They are an important reason for choosing to expand our presence here,” said Mads Krosgaard Thomsen, chief science officer at Novo Nordisk headquarters in Copenhagen.
The technology center where Novo Nordisk Research U.S. is located within the Greater New Brunswick Innovation Zone, one of three zones in New Jersey designed to support the expansion of technological and life sciences industries. “With more research-based pharmaceutical companies than any other country in the world and more scientists per capita than any other state, New Jersey is an ideal place for the first-ever hemostasis research facility,” said Caren S. Franzini, chief executive officer of the New Jersey Economic Development Authority.
Novo Nordisk currently manufactures the recombinant factor VII product NovoSeven®. NovoSeven® is approved by the U.S. Food and Drug Administration (FDA) for the treatment of bleeding episodes in hemophilia A and B patients with inhibitors to factor VIII or factor IX. The product is also FDA-approved for the treatment of bleeding in patients with factor VII deficiency. In addition, Novo Nordisk manufactures and markets products for diabetes, growth hormone therapy and hormone replacement therapy.
Source: Novo Nordisk press release dated February 23, 2006